| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Streamex Corp.$0.86
+0.01 (+1.18%)
Market Cap
103.58 M
EPS
-9.85
P/E Ratio
-0.11 $
Value Trade
1.51 M
SEC Financials
Q1 2026Dilution Risk
Operating CF
-10.18 M
Total Assets
173.32 M
Total Liabilities
13.97 M
Equity
158.99 M
D/E Ratio
12,345
-7.85 %
Week
24.21 %
1 Month
-16.31 %
3 Month
765.25 %
6 Month
-99.03 %
5 Year
-99.73 %
All Time
Cash Data
Cash Position
6.86 M
Monthly Burn
3.39 M
Runway
0.9 mo
Burn Trend
SEC Filing
May 14, 2026
Overview
Volume
1.64 M
52 Week Range
0.49 - 14.11
% held by Insiders
35.46 %
% held by Institutions
24 %
Enterprise Value
111.72 M
Total Shares
91.48 M
Short %
10.28 %
Float Shares
54.16 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in STEX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Streamex Corp. (STEX) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
STEX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
STEX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
STEX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
STEX Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
STEX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
STEXStreamex Corp. and Orca Announce Launch of 24/7 Decentralized Secondary Liquidity Infrastructure for Tokenized Securities; GLDY the Inaugural Asset
Corp. and Orca Announce Launch of 24/7 Decentralized Secondary Liquidity Infrastructure for Tokenized Securities; GLDY the Inaugural PARK, Fla., May 27, 2026 - Streamex Corp. ("Streamex" or the "Company") (NASDAQ: STEX), a technology company building the tokenization ecosystem
Read more →STEXStreamex Corp. Appoints Former Microsoft and PayPal Lead Product Designer Kori Handy as Vice President of Product and Design
Corp. Appoints Former Microsoft and PayPal Lead Product Designer Kori Handy as Vice President of Product and Design PARK, Fla., May 26, 2026 - Streamex Corp. ("Streamex" or the "Company") (NASDAQ: STEX), a technology company building the tokenization ecosystem for all real-worl
Read more →STEXStreamex Corp. Clarifies and Refutes Inaccurate Claims Regarding Lock-Up Agreements; Co-Founders Morgan Lekstrom & Henry McPhie Enter into Voluntary 1 Year Lock-Up Agreements Winter Park, FL
Corp. Clarifies and Refutes Inaccurate Claims Regarding Lock-Up Agreements; Co-Founders Morgan Lekstrom & Henry McPhie Enter into Voluntary 1 Year Lock-Up Agreements Park, FL - March 27, 2026 - Streamex Corp. ("Streamex" or the "Company") (NASDAQ: STEX) today issued a statemen
Read more →STEXStreamex Corp. Appoints Christine Plummer, Former Global Controller at Coinbase and Managing Director at Morgan Stanley, as Chief Financial Officer
Corp. Appoints Christine Plummer, Former Global Controller at Coinbase and Managing Director at Morgan Stanley, as Chief Financial Officer PARK, Fla., March 16, 2026 - Streamex Corp. ("Streamex" or the "Company") (NASDAQ: STEX), a technology and infrastructure company focused o
Read more →STEXStreamex Corp. Appoints Shawn Matthews, Former CEO of Cantor Fitzgerald & Co. & Founder and CIO of Hondius Capital Management, to Board of Directors
Streamex Corp. Appoints Shawn Matthews, Former CEO of Cantor Fitzgerald & Co. & Founder and CIO of Hondius Capital Management, to Board of Directors Fla., March 03, 2026 (GLOBE NEWSWIRE) - Streamex Corp. ("Streamex" or the "Company") (NASDAQ: STEX), a leader in institutional-g
Read more →STEXStreamex Corp. (NASDAQ: STEX) Appoints Morgan Lekstrom as Executive Chairman, & Announces Completed Repayment of Convertible Debenture and Cancellation of SEPA Winter Park, FL
Corp. (NASDAQ: STEX) Appoints Morgan Lekstrom as Executive Chairman, & Announces Completed Repayment of Convertible Debenture and Cancellation of SEPA Park, FL - February 9, 2026 - Streamex Corp. ("Streamex" or the "Company") (NASDAQ: STEX), a leader in institutional-grade tok
Read more →STEXStreamex Corp. (NASDAQ: STEX) Appoints Anthony Marciano, Clinical Professor of Finance at NYU Stern to Board of Directors Winter Park, FL
Streamex Corp. (NASDAQ: STEX) Appoints Anthony Marciano, Clinical Professor of Finance at NYU Stern to Board of Directors Winter Park, FL, - February 4, 2026 - Streamex Corp. ("Streamex" or the "Company") (NASDAQ: STEX), a leader in institutional-grade tokenization and digita
Read more →STEXStreamex Corp. (NASDAQ: STEX) Announces Issuance of Prepayment Notice for Previously Announced Convertible Debenture Financing & Notice of Termination for Standby Equity Purchase Agreement
Streamex Corp. (NASDAQ: STEX) Announces Issuance of Prepayment Notice for Previously Announced Convertible Debenture Financing & Notice of Termination for Standby Equity Purchase WINTER PARK, Fla., Jan. 23, 2026 (GLOBE NEWSWIRE) - Streamex Corp. ("Streamex" or the "Company") (
Read more →STEXStreamex Corp. (NASDAQ: STEX) Announces Proposed Public Offering Winter Park, FL
Corp. (NASDAQ: STEX) Announces Proposed Public Offering Park, FL - January 22, 2026 (GLOBE NEWSWIRE) - Streamex Corp. ("Streamex" or the "Company") (NASDAQ: STEX), a leader in institutional-grade tokenization of real-world assets and commodity-backed stablecoins, including GLDY
Read more →STEXStreamex Corp. (NASDAQ: STEX) Acquires 9.9% Strategic Equity Stake in Royalty and Streaming Firm Empress Royalty Corp. Through a Premium Priced Share-for-Share Transaction at US$5.00 STEX with a Leading Institutional Inv
Corp. (NASDAQ: STEX) Acquires 9.9% Strategic Equity Stake in Royalty and Streaming Firm Empress Royalty Corp. Through a Premium Priced Share-for-Share Transaction at US$5.00 STEX with a Leading Institutional Investment Firm ANGELES, CA - December 11, 2025 - Streamex Corp. ("Str
Read more →STEXStreamex Corp. (NASDAQ: STEX) Announces Appointment of Kevin Gopaul, Global Financial Executive and ETF Pioneer to Its Board of Directors
Corp. (NASDAQ: STEX) Announces Appointment of Kevin Gopaul, Global Financial Executive and ETF Pioneer to Its Board of Directors ANGELES, Nov. 18, 2025 (GLOBE NEWSWIRE) - Streamex Corp. ("Streamex" or the "Company") (NASDAQ: STEX), a leader in institutional-grade tokenization a
Read more →STEXStreamex Corp. (NASDAQ: STEX) Announces Gold Bullion Purchases & Closing of Initial USD $25,000,000 Tranche of the Previously Announced Financing; All Net Proceeds Deployed into Physical Gold Bullion USD $25,000,000 tran
Corp. (NASDAQ: STEX) Announces Gold Bullion Purchases & Closing of Initial USD $25,000,000 Tranche of the Previously Announced Financing; All Net Proceeds Deployed into Physical Gold Bullion $25,000,000 tranche from the previously announced July 2025 financing initiates Streame
Read more →STEXStreamex Corp. (NASDAQ: STEX) Announces Nasdaq Approval for Continued Listing on Nasdaq Capital Market & Shareholder Meeting on
Corp. (NASDAQ: STEX) Announces Nasdaq Approval for Continued Listing on Nasdaq Capital Market & Shareholder Meeting on November 4, Angeles, CA - October 30, 2025 (GLOBE NEWSWIRE) - Streamex Corp. ("Streamex" or the "Company") (NASDAQ: STEX), an institutional commodity tokenizat
Read more →STEXBioSig Technologies, Inc. Announces Corporate Rebrand to Streamex Corp. Strategic Rebranding to Focus on Expanded Business Model and Growth Strategy. New Ticker Symbol "STEX". LOS ANGELES & VANCOUVER, British Columbia
Technologies, Inc. Announces Corporate Rebrand to Streamex Corp. Rebranding to Focus on Expanded Business Model and Growth Strategy. New Ticker Symbol "STEX". ANGELES & VANCOUVER, British Columbia - September 10, 2025 - - BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig"), wh
Read more →STEXBioSig Technologies Inc. Announces Proposed Public Offering Los Angeles, CA
Technologies Inc. Announces Proposed Public Offering Angeles, CA, Aug. 13, 2025 (GLOBE NEWSWIRE) - BioSig Technologies, Inc. ("BioSig" or the "Company") which recently merged with Streamex Exchange Corporation ("Streamex") (NASDAQ: BSGM) today announced its intention to offer s
Read more →STEXBioSig Technologies, Inc. and Streamex Exchange Corporation Announce Definitive Agreements for up to $1,100,000,000 ($1.1B USD) in Growth Financing to Launch Gold Backed Treasury Management Strategy and to Rapidly Expand
Technologies, Inc. and Streamex Exchange Corporation Announce Definitive Agreements for up to $1,100,000,000 ($1.1B USD) in Growth Financing to Launch Gold Backed Treasury Management Strategy and to Rapidly Expand RWA Tokenization for the Commodities Markets BioSig Technologi
Read more →STEXStreamex and BioSig Announce the Successful Closing of Share Exchange Transaction and Executive Leadership Changes Bringing a First-Mover Real World Asset Tokenization Company to the Nasdaq
and BioSig Announce the Successful Closing of Share Exchange Transaction and Executive Leadership Changes Bringing a First-Mover Real World Asset Tokenization Company to the Nasdaq Angeles, CA and Vancouver, BC, May 28, 2025 (GLOBE NEWSWIRE) - BioSig Technologies, Inc. (Nasdaq:
Read more →STEXBioSig Technologies, Inc. Signs Definitive Share Exchange Agreement with Streamex Exchange Corp. to Launch First-Mover Real-World Asset (RWA) Tokenization Company Bringing Commodity Markets On-Chain.
Technologies, Inc. Signs Definitive Share Exchange Agreement with Streamex Exchange Corp. to Launch First-Mover Real-World Asset (RWA) Tokenization Company Bringing Commodity Markets On-Chain. Angeles, CA and Vancouver, BC, May 23, 2025 (GLOBE NEWSWIRE) - BioSig Technologies, I
Read more →STEXCONFIDENTIAL Letter of Intent
Wilshire Blvd., Ste. 745 Proposed Merger Transaction between BioSig Technologies, Inc. and Streamex Exchange Corporation Letter of Intent (this "LOI") summarizes the principal terms relating to a proposed merger or other business combination (the "Merger"), pursuant to which S
Read more →STEXBioSig Regains Compliance with Nasdaq's Minimum Bid Price Requirement Los Angeles, CA
Regains Compliance with Nasdaq's Minimum Bid Price Requirement Angeles, CA, November 13, 2024 -BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or "Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, t
Read more →STEXBioSig Technologies Appoints Mr. Ferdinand Groenewald to Position of Interim Chief Financial Officer and Principal Accounting Officer WESTPORT, CT
Technologies Appoints Mr. Ferdinand Groenewald to Position of Interim Chief Financial Officer and Principal Accounting Officer CT, June 10, 2024 -BioSig Technologies, Inc. (NASDAQ: BSGM) or ("BioSig" or "the Company"), a medical technology company delivering unprecedented accur
Read more →STEXBioSig Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Westport, CT
Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules CT, May 30, 2024 (GLOBE NEWSWIRE) - BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company") a medical technology company committed to delivering unprecedented accuracy and preci
Read more →STEXBioSig Technologies, Inc. Announces New Appointments to its Now Fully Constituted Board of Directors, which is Comprised of 5 Board Members, 3 Independent WESTPORT, CT
Technologies, Inc. Announces New Appointments to its Now Fully Constituted Board of Directors, which is Comprised of 5 Board Members, CT, May 03, 2024 -BioSig Technologies, Inc. (NASDAQ: BSGM) or ("BioSig" or "the Company"), a medical technology company delivering unprecedented
Read more →STEXBioSig Technologies, Inc. Appoints Mr. Anthony Amato to Position of Chief Executive Officer, Effective Immediately Mr. Amato will also serve on the Company's Board of Directors WESTPORT, CT
Technologies, Inc. Appoints Mr. Anthony Amato to Position of Chief Executive Officer, Effective Immediately Amato will also serve on the Company's Board of Directors CT, April 30, 2024 -BioSig Technologies, Inc. (NASDAQ: BSGM) or ("BioSig" or "the Company"), a medical technolo
Read more →STEXBioSig's PURE EP Platform with New Near Field Tracking Algorithm Surpasses 100 Patient Cases Company sees clinical adoption and usage of its novel Near Field Tracking algorithm, proven to reduce ablation time by approxim
PURE EP Platform with New Near Field Tracking Algorithm Surpasses 100 Patient Cases CT, Feb. 06, 2024 (GLOBE NEWSWIRE) - BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company committed to delivering unprecedented accuracy and precisi
Read more →STEXBioSig Announces Reverse Stock Split Common Stock Will Begin Trading on Split-Adjusted Basis on
Announces Reverse Stock Split Common Stock Will Begin Trading on Split-Adjusted Basis on February 2, 2024 CT, January 31, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company committed to delivering unprece
Read more →STEXBioSig Announces Cost Reductions to Improve its Financial Standing and Shifts its Core Strategy Cost Savings Targeted to Reduce Cash Burn by 50% Core Strategy Shifts to Business Development and Distribution Partnerships
Announces Cost Reductions to Improve its Financial Standing and Shifts its Core Strategy Cost Savings Targeted to Reduce Cash Burn by 50% Core Strategy Shifts to Business Development and Distribution Partnerships CT, January 30, 2024 (GLOBE NEWSWIRE) - BioSig Technologies,
Read more →STEXLETTER TO SHAREHOLDERS December 2023 Dear fellow shareholders, As we approach the end of 2023, I want to share with you BioSig's important achievements of the past 12 months, showcase our strengths and strategies, addres
fellow shareholders, we approach the end of 2023, I want to share with you BioSig's important achievements of the past 12 months, showcase our strengths and strategies, address our challenges, and offer insights about the year ahead. year, we completed BioSig's business transi
Read more →STEXBioSig Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Westport, CT
Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules CT, Nov. 13, 2023 - BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company") a medical technology company committed to delivering unprecedented accuracy and precision to intrac
Read more →STEXBioSig Appoints Global MedTech Leader Fred Hrkac as New Executive VP 32-year career in medical device and electrophysiology business expansion for industry bellwethers; led multiple company exits including a $1B sale in
Appoints Global MedTech Leader Fred Hrkac as New Executive VP career in medical device and electrophysiology business expansion for industry bellwethers; led multiple company exits including a $1B of leadership team that grew Johnson & Johnson's original cardiology/electrophysi
Read more →STEXSECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2023 BioSig Technologies, Inc. (Exact name of registrant as specified in its charter)
Read more →STEXLetter to Shareholders: The year in review - what a difference 12 months make! Dear BioSig Shareholder: On behalf of BioSig Technologies, I wanted to extend a continued thank you for your ownership in the Company and for
Letter to Shareholders: The year in review - what a difference 12 months make! Dear BioSig Shareholder: On behalf of BioSig Technologies, I wanted to extend a continued thank you for your ownership in the Company and for your support. We wouldn't be here without you. Our organ
Read more →STEXBioSig Technologies, Inc. Shareholder Letter December 2017 Dear BioSig Technologies, Inc. Shareholder: As the current year draws to a close, management felt it was an appropriate time to reflect on the achievements that
BioSig Technologies, Inc. Shareholder Letter December 2017 Dear BioSig Technologies, Inc. Shareholder: As the current year draws to a close, management felt it was an appropriate time to reflect on the achievements that we have accomplished and express our new goals for the fut
Read more →STEXIP veteran Andrew Filler joins BioSig Technologies' Board of Directors Santa Monica, CA
IP veteran Andrew Filler joins BioSig Technologies' Board of Directors Santa Monica, CA, November 10, 2017 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an
Read more →STEXBioSig Technologies, Inc. Shareholder Letter April 2017 Dear BioSig Technologies, Inc. Shareholder: I am pleased to report on some of the recent developments at BioSig Technologies, Inc. (OTCQB: BSGM), most notably, the
BioSig Technologies, Inc. Shareholder Letter April 2017 Dear BioSig Technologies, Inc. Shareholder: I am pleased to report on some of the recent developments at BioSig Technologies, Inc. (OTCQB: BSGM), most notably, the collaboration with Mayo Clinic physicians. This new, expan
Read more →STEXBioSig Technologies Announces Strategic Partnership with Mayo Clinic Ten-year agreement provides know-how, intellectual property development and clinical resources to commercialize the PURE EP System and develop future t
BioSig Technologies Announces Strategic Partnership with Mayo Clinic Ten-year agreement provides know-how, intellectual property development and clinical resources to commercialize the PURE EP System and develop future technologies Minneapolis, MN, March 17, 2017-- BioSig Techn
Read more →STEXcorporate presentation 2017 Symbol: BSGM Disclaimer Symbol:BSGM * This presentation contains forward-looking statements including statements that address activities, events or developments that BioSig expects, believes o
corporate presentation 2017 Symbol: BSGM Disclaimer Symbol:BSGM * This presentation contains forward-looking statements including statements that address activities, events or developments that BioSig expects, believes or anticipates will or may occur in the future, such as pred
Read more →STEXBioSig Technologies Announces Advanced Research Program with Mayo Clinic MINNEAPOLIS, MN
BioSig Technologies Announces Advanced Research Program with Mayo Clinic MINNEAPOLIS, MN, March 23, 2016 - BioSig Technologies, Inc. (OTCQB:BSGM) today announced the establishment of an advanced research program with Dr. Samuel Asirvatham at the Mayo Clinic in Rochester, Minneso
Read more →STEXFOURTH AMENDMENT TO THE BIOSIG TECHNOLOGIES, INC. 2012 EQUITY INCENTIVE PLAN This FOURTH AMENDMENT TO THE BIOSIG TECHNOLOGIES, INC. 2012 EQUITY INCENTIVE PLAN (this " Amendment "), adopted as of
BIOSIG TECHNOLOGIES, INC. 2012 EQUITY INCENTIVE PLAN This FOURTH AMENDMENT TO THE BIOSIG TECHNOLOGIES, INC. 2012 EQUITY INCENTIVE PLAN (this "Amendment"), adopted as of May 22, 2015, subject to stockholder approval, is made and entered into by BioSig Technologies, Inc., a Delawa
Read more →STEXBioSig Appoints Patrick Gallagher to its Board of Directors Los Angeles, CA
BioSig Appoints Patrick Gallagher to its Board of Directors Los Angeles, CA - July 22, 2014 - BioSig Technologies, a company that has developed and is commercializing its proprietary, PURE EP technology platform designed to significantly improve the clinical value of cardiac rec
Read more →STEXBioSig Names Med Devices Veteran Exec Gregory D. Cash CEO, President & Director Los Angeles, CA
BioSig Names Med Devices Veteran Exec Gregory D. Cash CEO, President & Director Los Angeles, CA - July 21, 2014 - BioSig Technologies, a company that has developed and is commercializing its proprietary PURE EP technology platform designed to significantly improve the clinical v
Read more →Competitive Position
How STEX ranks across every disease it competes inCompetitive Position is a premium feature
See how STEX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial